T-CURX has been invited to present on clinical advances of in vivo CAR-T therapies at the 2026 Dubai Stem Cell Congress in Dubai, UAE, and to sign an MoU for a strategic partnership with FSG-Lab, Dubai
The 4th international Dubai Stem Cell Congress 2026 hosted 400 international delegates and key opinion leaders in the field of cell therapies from Europe, Asia, North America and the Middle East region.
Ulf Grawunder, CEO of T-CURX, was invited to a presentation about recent clinical advances in in vivo CAR-T therapies. At the Opening Ceremony of the event, the CEOs of T-CURX and the First Stem Cell and Genomics Laboratory (FSG-Lab) also signed an MoU for a strategic partnership intended to bring T-CURX’s non-viral CAR-T therapies to Dubai and the Middle East region.